Investors sentiment decreased to 1 in 2019 Q2. Its down 0.04, from 1.04 in 2019Q1. It dived, as 37 investors sold Emergent BioSolutions Inc. shares while 66 reduced holdings. 27 funds opened positions while 76 raised stakes. 43.78 million shares or 2.93% more from 42.54 million shares in 2019Q1 were reported.
Sei owns 26,870 shares. Mackenzie Fincl reported 4,820 shares or 0% of all its holdings. First Hawaiian Bancshares invested in 12,642 shares or 0.03% of the stock. Pitcairn Company reported 11,242 shares. Cubist Systematic Strategies Ltd Liability Co holds 0.01% or 10,733 shares in its portfolio. Kbc Gru Nv invested in 2,611 shares. Putnam Invs Ltd Limited Liability Company stated it has 0.02% in Emergent BioSolutions Inc. (NYSE:EBS). Qs Investors Limited Liability Corporation holds 75,167 shares. Bridgeway Capital Mgmt holds 14,500 shares. Northwestern Mutual Wealth Management Co holds 0% of its portfolio in Emergent BioSolutions Inc. (NYSE:EBS) for 92 shares. Virginia Retirement System Et Al has invested 0.01% in Emergent BioSolutions Inc. (NYSE:EBS). Deutsche Comml Bank Ag reported 119,239 shares. Tower Research Cap Ltd (Trc) has invested 0% of its portfolio in Emergent BioSolutions Inc. (NYSE:EBS). Moreover, Voya Investment Mngmt Limited Co has 0.05% invested in Emergent BioSolutions Inc. (NYSE:EBS). The Michigan-based Ls Inv Ltd Liability has invested 0% in Emergent BioSolutions Inc. (NYSE:EBS).
The stock of Emergent Biosolutions Inc (NYSE:EBS) registered an increase of 7.57% in short interest. EBS’s total short interest was 3.83 million shares in December as published by FINRA. Its up 7.57% from 3.56M shares, reported previously. With 476,500 shares average volume, it will take short sellers 8 days to cover their EBS’s short positions.
The stock increased 0.68% or $0.37 during the last trading session, reaching $54.03. About 198,220 shares traded. Emergent BioSolutions Inc. (NYSE:EBS) has declined 16.70% since December 4, 2018 and is downtrending. It has underperformed by 16.70% the S&P500.
Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. The company has market cap of $2.79 billion. The Company’s products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. It has a 675.31 P/E ratio. The companyÂ’s marketed products include BioThrax, an anthrax vaccine; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT for the treatment of botulinum disease; vaccinia immune globulin intravenous that addresses adverse events from smallpox vaccination; reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride.
Emergent BioSolutions Inc. (NYSE:EBS) Ratings Coverage
Among 2 analysts covering Emergent BioSolutions (NYSE:EBS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Emergent BioSolutions has $6500 highest and $6400 lowest target. $64.50’s average target is 19.38% above currents $54.03 stock price. Emergent BioSolutions had 2 analyst reports since September 4, 2019 according to SRatingsIntel. The firm has “Outperform” rating given on Wednesday, September 4 by Wells Fargo.
More notable recent Emergent BioSolutions Inc. (NYSE:EBS) news were published by: Globenewswire.com which released: “Emergent BioSolutions Announces Exercise by BARDA of the First Contract Option, Valued at $261 Million, to Procure Doses of AV7909 Anthrax Vaccine Candidate for the Strategic National Stockpile – GlobeNewswire” on July 30, 2019, also Globenewswire.com with their article: “Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months Ended June 30, 2019 – GlobeNewswire” published on August 01, 2019, Fool.com published: “The FDA Really Wants These Opioid Overdose Drugmakers to Succeed – Motley Fool” on September 25, 2019. More interesting news about Emergent BioSolutions Inc. (NYSE:EBS) were released by: Seekingalpha.com and their article: “Emergent Bio nabs $261M order for anthrax vaccine – Seeking Alpha” published on July 30, 2019 as well as Globenewswire.com‘s news article titled: “Emergent BioSolutions to Release Third Quarter 2019 Financial Results and Conduct a Conference Call on November 6, 2019 – GlobeNewswire” with publication date: October 09, 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.